Biotech Analysts discuss Rhythm Pharmaceuticals’ (RYTM) Setmelanotide for the opportunity to treat acquired hypothalamic obesity on an Analyst/Industry conference call to be held on July 14 .
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals price target raised to $119 from $94 at Guggenheim
- Rhythm Pharmaceuticals price target raised to $110 from $76 at Oppenheimer
- Rhythm Pharmaceuticals 2.059M share Spot Secondary priced at $85.00
- Rhythm Pharmaceuticals prices 2.06M shares at $85.00 in upsized public offering
- Rhythm Pharmaceuticals price target raised to $129 from $91 at Wells Fargo